Cargando…

PD‐L1/p‐STAT3 promotes the progression of NSCLC cells by regulating TAM polarization

PD‐L1 is closely related to the immune escape process of tumour cells, and targeted PD‐L1 clinical immunotherapy has been implemented. However, whether PD‐L1 is involved in TAM/M2 polarization in the TME of NSCLC and its specific mechanism remain unclear. In order to clarify the specific role of PD‐...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Rui, Meng, Ziqi, Wu, Xuwei, Zhang, Meihua, Piao, Zhengri, Jin, Tiefeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716221/ https://www.ncbi.nlm.nih.gov/pubmed/36372977 http://dx.doi.org/10.1111/jcmm.17610

Ejemplares similares

PD-L1 mediates triple-negative breast cancer evolution via the regulation of TAM/M2 polarization
por: Meng, Ziqi, et al.
Publicado: (2022)

IDO1 Promotes the Progression of NSCLC by Regulating the Polarization of M2 Macrophages
por: Chen, Xiao, et al.
Publicado: (2023)

ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation
por: Chen, Xiaozheng, et al.
Publicado: (2021)

M1-like TAMs are required for the efficacy of PD-L1/PD-1 blockades in gastric cancer
por: Zhao, Rui, et al.
Publicado: (2020)

Tumor‐associated macrophages (TAMs)‐derived osteopontin (OPN) upregulates PD‐L1 expression and predicts poor prognosis in non‐small cell lung cancer (NSCLC)
por: Li, Yue, et al.
Publicado: (2021)

M(2)-TAM subsets altered by lactic acid promote T-cell apoptosis through the PD-L1/PD-1 pathway
por: Shan, Tao, et al.
Publicado: (2020)

CAIX Regulates GBM Motility and TAM Adhesion and Polarization through EGFR/STAT3 under Hypoxic Conditions
por: Huang, Bor-Ren, et al.
Publicado: (2020)

Tumor-derived exosomal HMGB1 promotes esophageal squamous cell carcinoma progression through inducing PD1(+) TAM expansion
por: Li, Bin, et al.
Publicado: (2019)

Research Progress of Anti-PD-1/PD-L1 Immunotherapy Related Mechanisms and Predictive Biomarkers in NSCLC
por: Bie, Fenglong, et al.
Publicado: (2022)

Smoking‐Induced M2‐TAMs, via circEML4 in EVs, Promote the Progression of NSCLC through ALKBH5‐Regulated m6A Modification of SOCS2 in NSCLC Cells
por: Cheng, Cheng, et al.
Publicado: (2023)

Targeted delivery of chlorogenic acid by mannosylated liposomes to effectively promote the polarization of TAMs for the treatment of glioblastoma
por: Ye, Jun, et al.
Publicado: (2020)

Long non-coding RNA NBR2 suppresses the progress of colorectal cancer in vitro and in vivo by regulating the polarization of TAM
por: Lai, Fuji, et al.
Publicado: (2021)

Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects
por: Peters, Solange, et al.
Publicado: (2022)

Blocking the Notch signal transduction pathway promotes tumor growth in osteosarcoma by affecting polarization of TAM to M2 phenotype
por: Ren, Shuguang, et al.
Publicado: (2020)

PD-L1 promoter methylation mediates the resistance response to anti-PD-1 therapy in NSCLC patients with EGFR-TKI resistance
por: Zhang, Yan, et al.
Publicado: (2017)

RPS9 promotes the progression of NSCLC via activation Stat3 and Erk signaling pathways
por: Kong, Yiru, et al.
Publicado: (2022)

The NR_109/FUBP1/c-Myc axis regulates TAM polarization and remodels the tumor microenvironment to promote cancer development
por: Zhang, Cong, et al.
Publicado: (2023)

Ezrin promotes pancreatic cancer cell proliferation and invasion through activating the Akt/mTOR pathway and inducing YAP translocation
por: Quan, Chunji, et al.
Publicado: (2019)

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
por: Niu, Mengke, et al.
Publicado: (2021)

AKT-STAT3 Pathway as a Downstream Target of EGFR Signaling to Regulate PD-L1 Expression on NSCLC cells
por: Abdelhamed, Sherif, et al.
Publicado: (2016)

The Role of TAMs in Tumor Microenvironment and New Research Progress
por: Feng, Yawei, et al.
Publicado: (2022)

STAT1 deficiency supports PD-1/PD-L1 signaling resulting in dysfunctional TNFα mediated immune responses in a model of NSCLC
por: Friedrich, Juliane, et al.
Publicado: (2018)

Can Ipilimumab restore immune response in advanced NSCLC after progression on anti‐PD‐1/PD‐L1 agents?
por: Sternschuss, Michal, et al.
Publicado: (2020)

Evaluation of the roles and regulatory mechanisms of PD-1 target molecules in NSCLC progression
por: Zhang, Yun-Qiang, et al.
Publicado: (2021)

TAM-targeted reeducation for enhanced cancer immunotherapy: Mechanism and recent progress
por: Shen, Xinyuan, et al.
Publicado: (2022)

Differential expression of PD-L1 and PD-L2 is associated with the tumor microenvironment of TILs and M2 TAMs and tumor differentiation in non-small cell lung cancer
por: Sumitomo, Ryota, et al.
Publicado: (2022)

TAM-ing T cells in the tumor microenvironment: implications for TAM receptor targeting
por: Peeters, Marlies J. W., et al.
Publicado: (2019)

Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics
por: Zhang, Jie, et al.
Publicado: (2015)

Progranulin induces immune escape in breast cancer via up-regulating PD-L1 expression on tumor-associated macrophages (TAMs) and promoting CD8(+) T cell exclusion
por: Fang, Wenli, et al.
Publicado: (2021)

Exercise modulates polarization of TAMs and expression of related immune checkpoints in mice with lung cancer
por: Ge, Zhe, et al.
Publicado: (2022)

HDAC10 Is Positively Associated With PD-L1 Expression and Poor Prognosis in Patients With NSCLC
por: Liu, Xiaomei, et al.
Publicado: (2020)

PIG3 promotes NSCLC cell mitotic progression and is associated with poor prognosis of NSCLC patients
por: Li, Ming, et al.
Publicado: (2017)

Differential TAM receptor–ligand–phospholipid interactions delimit differential TAM bioactivities
por: Lew, Erin D, et al.
Publicado: (2014)

Correction to: Progranulin induces immune escape in breast cancer via up-regulating PD-L1 expression on tumor-associated macrophages (TAMs) and promoting CD8(+) T cell exclusion
por: Fang, Wenli, et al.
Publicado: (2022)

miR-196b-5p-mediated downregulation of FAS promotes NSCLC progression by activating IL6-STAT3 signaling
por: Huang, Xiangjie, et al.
Publicado: (2020)

YAP regulates PD-L1 expression in human NSCLC cells
por: Miao, Jinbai, et al.
Publicado: (2017)

PD-L1 Immunohistochemistry Comparability and Their Correlation with Clinical Characteristics in NSCLC
por: Wu, Chiao-En, et al.
Publicado: (2020)

Various impacts of driver mutations on the PD-L1 expression of NSCLC
por: Chu, Cheng-Hsiang, et al.
Publicado: (2022)

TAM macrophages promote growth and metastasis within the cancer ecosystem
por: Zarif, Jelani C, et al.
Publicado: (2014)

SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges
por: Chen, Yu, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8k8r6vnbkn3g9te1lqvo8ht03l